Evaluation of hypoxia-mediated growth factors in a novel bladder cancer animal model

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 4225-4231

  Fechner, Guido ^a   Müller, Georg ^a   Schmidt, Doris ^a   Garbe, Stefan ^a   Hauser, Stefan ^a   Vaupel, Peter ^b   Müller, Stefan C ^a  

^a UNIVERSITY OF BONN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Bladder cancer; Hemoglobin level; Hypoxia; VEGF expression

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; HEMOGLOBIN BLOOD LEVEL; HYPOXIA; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; MALE; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL HYPOXIA; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; OXYGEN; RATS; RATS, WISTAR; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37549021801     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Lehmann J, Retz M, Wiemers C, Beck J, Thuroff J, Weining C, Albers P, Frohneberg D, Becker T, Funke PJ, Walz P, Langbein S, Reiher F, Schiller M, Miller K, Roth S, Kalble T, Sternberg D, Wellek S and Stockle M: Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 23(22): 4963-4974, 2005.
2. Sternberg C and Calabro F: Adjuvant chemotherapy for bladder cancer. Expert Rev Anticancer Ther 5(6): 987-992, 2005.
3. Tinker A, Winquist E, Canil C, Moore M, Murray RN and Chi KN: A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer. Am J Clin Oncol 29(1): 3-7, 2006.
4. Artz A, Stadler WM, Vogelzang NJ, Zimmerman T and Ryan C: A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. Am J Clin Oncol 28(2): 109-113, 2005.
5. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M and Adam L: Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 65(22): 10524-10535, 2005.
6. Dominguez-Escrig JL, Kelly JD, Neal DE, King SM and Davies BR: Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 10(14): 4874-4884, 2004.
7. Rocchetti R, Talevi S, Margiotta C, Calza R, Corallini A and Possati L: Antiangiogenic drugs for chemotherapy of bladder tumours. Chemotherapy 51(6): 291-299, 2005.
8. Vaupel P: The role of hypoxia-induced factors in tumor progression. Oncologist 9(Suppl 5): 10-17, 2004.
9. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD and Maity A: EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-Independent and HIF-1-dependent mechanisms. Cancer Res 66(6): 3197-3204, 2006.
10. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA, Keane MP and Strieter RM: Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280(23): 22473-22481, 2005.
11. Bellezza I, Bracarda S, Caserta C and Minelli A: Targeting of EGFR tyrosine kinase by ZD1839 (Iressa) in androgen-responsive prostate cancer in vitro. Mol Genet Metab 88(2): 114-122, 2006.
12. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B and Skobe M: Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 66(5): 2650-2657, 2006.
13. Bamias A, Moulopoulos LA, Koutras A, Aravantinos G, Fountzilas G, Pectasides D, Kastritis E, Gika D, Skarlos D, Linardou H, Kalofonos HP and Dimopoulos MA: The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer 106(2): 297-303, 2006.
14. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23(21): 4602-4608, 2005.
15. Palit V, Phillips RM, Puri R, Shah T and Bibby MC: Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncol Rep 14(4): 909-913, 2005.
16. Theodoropoulos VE, Lazaris AC, Kastriotis I, Spiliadi C, Theodoropoulos GE, Tsoukala V, Patsouris E and Sofras F: Evaluation of hypoxia-inducible factor lalpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 95(3): 425-431, 2005.
17. Stuben G, Thews O, Pottgen C, Knuhmann K, Vaupel P and Stuschke M: Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 127(6): 346-350, 2001.
18. Yang J, Wu HF, Qian LX, Zhang W, Hua LX, Yu ML, Wang Z, Xu ZQ, Sui YG and Wang XR: Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression. Asian J Androl 8(2): 169-175, 2006.
19. Kondo Y, Hamada J, Kobayashi C, Nakamura R, Suzuki Y, Kimata R, Nishimura T, Kitagawa T, Kunimoto M, Imura N and Hara S: Overexpression of hypoxia-inducible factor-1alpha in renal and bladder cancer cells increases tumorigenic potency. J Urol 173(5): 1762-1766, 2005.
20. Habuchi T, Marberger M, Droller MJ, Hemstreet GP, 3rd, Grossman HB, Schalken JA, Schmitz-Drager BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y and Lokeshwar VB: Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 66(6 Suppl 1): 64-74, 2005.
21. Cardones AR and Banez LL: VEGF inhibitors in cancer therapy. Curr Pharm Des 12(3): 387-394, 2006.
22. Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, Sheppard FC, Parker CA, Stratford IJ and Williams KJ: Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 69(2): 411-418, 2006.
23. Dunst J, Stadler P, Becker A, Lautenschlager C, Pelz T, Hansgen G, Molls M and Kuhnt T: Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 179(8): 521-526, 2003.
24. Jiang Hand Feng Y: Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer. Int J Gynecol Cancer 16(Suppl 1): 405-412, 2006.
25. Schellhammer PF, Kaplan MH, Pinsky CM and Whitmore WF Jr: Study of local and systemic effects of intravesical BCG. Urology 6(5): 562-567, 1975.
26. Perabo FG and Muller SC: Current and new strategies in immunotherapy for superficial bladder cancer. Urology 64(3): 409-421, 2004.
27. Vaupel P, Mayer A and Hockel M: Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol 182(2): 63-71, 2006.